Joseph Romanelli
Patrimonio netto: 4 M $ in data 30/09/2026
Patrimonio netto: 4 M $ in data 30/09/2026
Joseph Romanelli is currently President, Chief Executive Officer & Director at Tessera Therapeutics, Inc. since 2026.
Mr. Romanelli is Chief Executive Officer & Partner at Flagship Pioneering, LLC starting in 2026.
Mr. Romanelli serves as an Independent Director at Kimberly-Clark Corp.
beginning in 2024.
Former roles include Chief Executive Officer at CORXEL Pharmaceuticals (Shanghai) Co., Ltd. from 2021 to 2022.
Mr. Romanelli was Head-Investor Relations at Merck & Co., Inc. from 1996 to 2015.
Mr. Romanelli held the position of Head-Investor Relations at Schering-Plough Corp.
USA. Mr. Romanelli was President-Human Health International at Merck & Co., Inc. Education includes an undergraduate degree from the University of Delaware and an MBA from Gabelli School of Business.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 26/01/2026 | 28.739 ( 0% ) | 4 M $ | 30/09/2026 | |
| 02/01/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| KIMBERLY-CLARK CORPORATION | Direttore/Membro del Consiglio | 13/11/2024 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that writes therapeutic messages into the genome to treat diseases | Amministratore Delegato | 23/07/2026 |
Flagship Pioneering, Inc.
Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Amministratore Delegato | 01/01/2026 |
| Società | Posizione | Fine |
|---|---|---|
Jixing Pharmaceutical Technology (Shanghai) Co. Ltd.
Jixing Pharmaceutical Technology (Shanghai) Co. Ltd. BiotechnologyHealth Technology Develops and commercializes novel therapeutics for cardiometabolic diseases | Amministratore Delegato | 01/07/2022 |
| MERCK & CO., INC. | Contatto Relazioni con gli Investitori | 01/07/2015 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Public Communications Contact | 04/11/2009 |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 8 |
|---|---|
Kimberly-Clark Corp.
Kimberly-Clark Corp. Household/Personal CareConsumer Non-Durables Manufactures paper based products and provides cleaning solutions | Consumer Non-Durables |
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Health Technology |
Flagship Pioneering, Inc.
Flagship Pioneering, Inc. Investment ManagersFinance Flagship Pioneering invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, life science tools & diagnostics, bioenergy, and cleantech sectors. It provides financing for seed, early and later-stage capital requirements. The firm makes co-investments and also acts as a lead investor. | Finance |
University of Delaware
University of Delaware Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gabelli School of Business
Gabelli School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that writes therapeutic messages into the genome to treat diseases | Health Technology |
Jixing Pharmaceutical Technology (Shanghai) Co. Ltd.
Jixing Pharmaceutical Technology (Shanghai) Co. Ltd. BiotechnologyHealth Technology Develops and commercializes novel therapeutics for cardiometabolic diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale